      <Protocol xmlns:cdr='cips.nci.nih.gov/cdr'>
       <ProtTitle>Phase II Study of Interleukin-2 in Patients With Mycosis Fungoides or Sezary Syndrome (Summary Last Modified 06/2000)</ProtTitle>
       <ProtType>clinical trial</ProtType>
       <ProtLowAge>18</ProtLowAge>
       <ProtHighAge>120</ProtHighAge>
       <ProtAgeCrit>18 and over</ProtAgeCrit>
       <ProtStatus>protocol is active</ProtStatus>
       <ProtStatusDate>2000-02-11T00:00:00.0</ProtStatusDate>
       <ProtEntryDate>2000-03-03T00:00:00.0</ProtEntryDate>
       <ProtEntryUser>KECKLEY</ProtEntryUser>
       <ProtChangeUser>DELIAS</ProtChangeUser>
       <ProtChangeDate>2000-05-15T00:00:00.0</ProtChangeDate>
       <ProtOrigTitle>Phase II Trial of Subcutaneous Injections of Interleukin-2 for the Treatment of Mycosis Fungoides or the Sezary Syndrome</ProtOrigTitle>
       <ProtShortTitle>Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome</ProtShortTitle>
       <ProtId>
        <ProtIdString>NU-96H7</ProtIdString>
        <ProtIdType>primary ID</ProtIdType>
       </ProtId>
       <ProtId>
        <ProtIdString>NCI-G00-1735</ProtIdString>
        <ProtIdType>NCI alternate ID</ProtIdType>
        <ProtIdCode>G</ProtIdCode>
       </ProtId>
       <ProtOrg>
        <ProtOrgName cdr:ref='CDR0000023018'>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</ProtOrgName>
        <ProtOrgRole>lead organization</ProtOrgRole>
        <ProtOrgScheduleType>normal</ProtOrgScheduleType>
        <ProtOrgEntryDate>2000-03-03T00:00:00.0</ProtOrgEntryDate>
        <ProtOrgEntryUser>KECKLEY</ProtOrgEntryUser>
        <ProtOrgStatus>protocol is active</ProtOrgStatus>
        <ProtOrgStatusDate>2000-02-11T00:00:00.0</ProtOrgStatusDate>
        <ProtOrgType>institutional</ProtOrgType>
        <ProtOrgProtId>NU-96H7</ProtOrgProtId>
        <ProtOrgPerson>
         <ProtOrgPersonName cdr:ref='CDR0000104421'>Isabel Melendez</ProtOrgPersonName>
         <ProtOrgPersonRole>protocol update person</ProtOrgPersonRole>
         <ProtOrgPersonEntryDate>2000-03-03T08:27:49.0</ProtOrgPersonEntryDate>
         <ProtOrgPersonEntryUser>KECKLEY</ProtOrgPersonEntryUser>
        </ProtOrgPerson>
        <ProtOrgPerson>
         <ProtOrgPersonName cdr:ref='CDR0000064709'>Timothy M. Kuzel</ProtOrgPersonName>
         <ProtOrgPersonRole>protocol chairman</ProtOrgPersonRole>
         <ProtOrgPersonEntryDate>2000-03-03T08:27:49.0</ProtOrgPersonEntryDate>
         <ProtOrgPersonEntryUser>KECKLEY</ProtOrgPersonEntryUser>
        </ProtOrgPerson>
        <ProtOrgStat>
         <ProtOrgStatValue>protocol is active</ProtOrgStatValue>
         <ProtOrgStatDate>2000-02-11T00:00:00.0</ProtOrgStatDate>
         <ProtOrgStatEntryDate>2000-03-03T00:00:00.0</ProtOrgStatEntryDate>
         <ProtOrgStatEntryUser>KECKLEY</ProtOrgStatEntryUser>
         <ProtOrgStatChangeDate>2000-03-03T00:00:00.0</ProtOrgStatChangeDate>
         <ProtOrgStatChangeUser>KECKLEY</ProtOrgStatChangeUser>
         <ProtOrgStatComments>Active per K. Davis; 04/00 ke.</ProtOrgStatComments>
        </ProtOrgStat>
       </ProtOrg>
       <ProtOrg>
        <ProtOrgName cdr:ref='CDR0000023018'>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</ProtOrgName>
        <ProtOrgRole>participant organization</ProtOrgRole>
        <ProtOrgScheduleType>none</ProtOrgScheduleType>
        <ProtOrgEntryDate>2000-03-03T00:00:00.0</ProtOrgEntryDate>
        <ProtOrgEntryUser>KECKLEY</ProtOrgEntryUser>
        <ProtOrgStatus>protocol has no status</ProtOrgStatus>
        <ProtOrgParent cdr:ref='CDR0000023018'>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</ProtOrgParent>
        <ProtOrgPerson>
         <ProtOrgPersonName cdr:ref='CDR0000064709'>Timothy M. Kuzel</ProtOrgPersonName>
         <ProtOrgPersonRole>principal investigator</ProtOrgPersonRole>
         <ProtOrgPersonEntryDate>2000-03-03T00:00:00.0</ProtOrgPersonEntryDate>
         <ProtOrgPersonEntryUser>KECKLEY</ProtOrgPersonEntryUser>
        </ProtOrgPerson>
       </ProtOrg>
       <ProtOrg>
        <ProtOrgName cdr:ref='CDR0000023337'>Boston Medical Center</ProtOrgName>
        <ProtOrgRole>participant organization</ProtOrgRole>
        <ProtOrgScheduleType>none</ProtOrgScheduleType>
        <ProtOrgEntryDate>2000-03-03T00:00:00.0</ProtOrgEntryDate>
        <ProtOrgEntryUser>KECKLEY</ProtOrgEntryUser>
        <ProtOrgStatus>protocol has no status</ProtOrgStatus>
        <ProtOrgParent cdr:ref='CDR0000023018'>Robert H. Lurie Comprehensive Cancer Center, Northwestern University</ProtOrgParent>
        <ProtOrgPerson>
         <ProtOrgPersonName cdr:ref='CDR0000071118'>Francine Marie Foss</ProtOrgPersonName>
         <ProtOrgPersonRole>principal investigator</ProtOrgPersonRole>
         <ProtOrgPersonEntryDate>2000-03-03T00:00:00.0</ProtOrgPersonEntryDate>
         <ProtOrgPersonEntryUser>KECKLEY</ProtOrgPersonEntryUser>
        </ProtOrgPerson>
       </ProtOrg>
       <ProtProcStatus>
        <ProtProcStatusValue>summary not ready for release</ProtProcStatusValue>
        <ProtProcStatusDate>2000-03-03T00:00:00.0</ProtProcStatusDate>
        <ProtProcEntryDate>2000-03-03T00:00:00.0</ProtProcEntryDate>
        <ProtProcEntryUser>KECKLEY</ProtProcEntryUser>
       </ProtProcStatus>
       <ProtProcStatus>
        <ProtProcStatusValue>logged in</ProtProcStatusValue>
        <ProtProcStatusDate>2000-03-03T00:00:00.0</ProtProcStatusDate>
        <ProtProcEntryDate>2000-03-03T00:00:00.0</ProtProcEntryDate>
        <ProtProcEntryUser>KECKLEY</ProtProcEntryUser>
       </ProtProcStatus>
       <ProtProcStatus>
        <ProtProcStatusValue>summary ready for release</ProtProcStatusValue>
        <ProtProcStatusDate>2000-05-15T00:00:00.0</ProtProcStatusDate>
        <ProtProcEntryDate>2000-05-15T00:00:00.0</ProtProcEntryDate>
        <ProtProcEntryUser>DELIAS</ProtProcEntryUser>
        <ProtProcChangeDate>2000-05-15T00:00:00.0</ProtProcChangeDate>
        <ProtProcChangeUser>DELIAS</ProtProcChangeUser>
       </ProtProcStatus>
       <ProtProcStatus>
        <ProtProcStatusValue>summary ready for release</ProtProcStatusValue>
        <ProtProcStatusDate>2000-05-15T09:45:32.0</ProtProcStatusDate>
        <ProtProcEntryDate>2000-05-15T09:45:32.0</ProtProcEntryDate>
        <ProtProcEntryUser>DELIAS</ProtProcEntryUser>
        <ProtProcChangeDate>2000-05-15T09:45:32.0</ProtProcChangeDate>
        <ProtProcChangeUser>DELIAS</ProtProcChangeUser>
       </ProtProcStatus>
       <ProtProcStatus>
        <ProtProcStatusValue>summary ready for release</ProtProcStatusValue>
        <ProtProcStatusDate>2000-05-15T09:45:33.0</ProtProcStatusDate>
        <ProtProcEntryDate>2000-05-15T09:45:33.0</ProtProcEntryDate>
        <ProtProcEntryUser>DELIAS</ProtProcEntryUser>
        <ProtProcChangeDate>2000-05-15T09:45:33.0</ProtProcChangeDate>
        <ProtProcChangeUser>DELIAS</ProtProcChangeUser>
       </ProtProcStatus>
       <ProtProcStatus>
        <ProtProcStatusValue>patient abstract written</ProtProcStatusValue>
        <ProtProcStatusDate>2000-06-14T10:40:06.0</ProtProcStatusDate>
        <ProtProcEntryDate>2000-06-14T10:40:06.0</ProtProcEntryDate>
        <ProtProcEntryUser>AJAMISON</ProtProcEntryUser>
       </ProtProcStatus>
       <ProtProduct>
        <ProtProductType>Cancer Information Product</ProtProductType>
        <ProtProductScope>in scope</ProtProductScope>
        <ProtProductIncludeFlag>Y</ProtProductIncludeFlag>
        <ProtProductReleaseDate>2000-06-01T00:00:00.0</ProtProductReleaseDate>
        <ProtProductNewDate>2000-06-01T00:00:00.0</ProtProductNewDate>
       </ProtProduct>
       <ProtProduct>
        <ProtProductType>Rare Disease Information Product</ProtProductType>
        <ProtProductScope>in scope</ProtProductScope>
        <ProtProductIncludeFlag>Y</ProtProductIncludeFlag>
        <ProtProductReleaseDate>2000-06-01T00:00:00.0</ProtProductReleaseDate>
        <ProtProductNewDate>2000-06-01T00:00:00.0</ProtProductNewDate>
       </ProtProduct>
       <ProtSponsor>NCI-sponsored</ProtSponsor>
       <ProtSponsor>NCI-sponsored trial in cancer center</ProtSponsor>
       <ProtStat>
        <ProtStatValue>protocol is active</ProtStatValue>
        <ProtStatDate>2000-02-11T00:00:00.0</ProtStatDate>
        <ProtStatEntryDate>2000-03-03T08:29:46.0</ProtStatEntryDate>
        <ProtStatEntryUser>KECKLEY</ProtStatEntryUser>
        <ProtStatChangeDate>2000-03-03T11:11:34.0</ProtStatChangeDate>
        <ProtStatChangeUser>KECKLEY</ProtStatChangeUser>
       </ProtStat>
       <ProtStat>
        <ProtStatValue>protocol has no status</ProtStatValue>
        <ProtStatDate>2000-03-03T00:00:00.0</ProtStatDate>
        <ProtStatEntryDate>2000-03-03T00:00:00.0</ProtStatEntryDate>
        <ProtStatEntryUser>KECKLEY</ProtStatEntryUser>
       </ProtStat>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000187123'>interleukin-2</ProtTermName>
        <ProtTermType>drug</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000182531'>phase II study</ProtTermName>
        <ProtTermType>protocol phase</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000185393'>interleukin therapy</ProtTermName>
        <ProtTermType>modality</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000182271'>recurrent cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000188309'>stage IV cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000182263'>stage III cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000188308'>stage II cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000188307'>stage I cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Cancer Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000187123'>interleukin-2</ProtTermName>
        <ProtTermType>drug</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000182531'>phase II study</ProtTermName>
        <ProtTermType>protocol phase</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000185393'>interleukin therapy</ProtTermName>
        <ProtTermType>modality</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000182271'>recurrent cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000188309'>stage IV cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000182263'>stage III cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000188308'>stage II cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtTerm>
        <ProtTermName cdr:ref='CDR0000188307'>stage I cutaneous T-cell lymphoma</ProtTermName>
        <ProtTermType>diagnosis</ProtTermType>
        <ProtTermProduct>Rare Disease Information Product</ProtTermProduct>
       </ProtTerm>
       <ProtPatAbstr>
        <ProtPatAbstrText>
*** MISSING FILE FOR pro14904.htm ***</ProtPatAbstrText>
        <ProtPatAbstrStat>on-line</ProtPatAbstrStat>
        <ProtPatAbstrStatDate>2000-06-14T10:40:06.0</ProtPatAbstrStatDate>
        <ProtPatAbstrEntryDate>2000-06-14T10:40:06.0</ProtPatAbstrEntryDate>
        <ProtPatAbstrEntryUser>AJAMISON</ProtPatAbstrEntryUser>
       </ProtPatAbstr>
       <ProtDosageForms>
        <ProtDosageFormsText>Not abstracted</ProtDosageFormsText>
        <ProtDosageFormsStat>on-line</ProtDosageFormsStat>
        <ProtDosageFormsStatDate>2000-03-03T00:00:00.0</ProtDosageFormsStatDate>
        <ProtDosageFormsEntryDate>2000-04-13T15:39:45.0</ProtDosageFormsEntryDate>
        <ProtDosageFormsEntryUser>SCHRISTE</ProtDosageFormsEntryUser>
        <ProtDosageFormsChangeUser>SCHRISTE</ProtDosageFormsChangeUser>
       </ProtDosageForms>
       <ProtDosageSchedule>
        <ProtDosageScheduleText>Not abstracted</ProtDosageScheduleText>
        <ProtDosageScheduleStat>on-line</ProtDosageScheduleStat>
        <ProtDosageScheduleStatDate>2000-03-03T00:00:00.0</ProtDosageScheduleStatDate>
        <ProtDosageScheduleEntryDate>2000-04-13T15:39:45.0</ProtDosageScheduleEntryDate>
        <ProtDosageScheduleEntryUser>SCHRISTE</ProtDosageScheduleEntryUser>
        <ProtDosageScheduleChangeUser>SCHRISTE</ProtDosageScheduleChangeUser>
       </ProtDosageSchedule>
       <ProtEndPoints>
        <ProtEndPointsText>Not abstracted</ProtEndPointsText>
        <ProtEndPointsStat>on-line</ProtEndPointsStat>
        <ProtEndPointsStatDate>2000-03-03T00:00:00.0</ProtEndPointsStatDate>
        <ProtEndPointsEntryDate>2000-04-13T15:39:45.0</ProtEndPointsEntryDate>
        <ProtEndPointsEntryUser>SCHRISTE</ProtEndPointsEntryUser>
        <ProtEndPointsChangeUser>SCHRISTE</ProtEndPointsChangeUser>
       </ProtEndPoints>
       <ProtEntryCriteria>
        <ProtEntryCriteriaText>--Disease Characteristics--

Histologically proven mycosis fungoides or Sezary syndrome
 Any stage

Measurable disease with 1 or more indicator lesions
 Evaluable disease for erythrodermic patients only

At least 2 weeks since prior therapy, if documented progressive disease (PD)

At least 4 weeks since prior therapy, if best response achieved without clear
evidence of PD

--Prior/Concurrent Therapy--

See Disease Characteristics

Biologic therapy:
 Not specified

Chemotherapy:
 See Disease Characteristics 

Endocrine therapy:
 No concurrent steroids

Radiotherapy:
 See Disease Characteristics 
 No concurrent radiotherapy

Surgery:
 Not specified

Other:
 No other concurrent proven or investigational antineoplastic therapy

--Patient Characteristics--

Age:
 18 and over 

Performance status:
 ECOG 0-2

Life expectancy:
 At least 3 months

Hematopoietic:
 WBC at least 3,000/mm3
 Absolute granulocyte count at least 1,000/mm3
 Platelet count at least 100,000/mm3 

Hepatic:
 Bilirubin no greater than 2.2 mg/dL

Renal:
 Creatinine no greater than 2.0 mg/dL

Cardiovascular:
 No New York Heart Association class III or IV heart disease
 No cardiac pacemaker
 No clinically significant peripheral venous insufficiency

Other:
 No other malignancy within the past 5 years except:
  Treated squamous cell or basal cell skin cancer 
  Treated carcinoma in situ of the cervix 
  Surgically treated other cancer 
 Not pregnant or nursing
 Negative pregnancy test
 Fertile patients must use effective contraception
 No active infection
 HIV negative
 No poorly controlled diabetes mellitus</ProtEntryCriteriaText>
        <ProtEntryCriteriaStat>on-line</ProtEntryCriteriaStat>
        <ProtEntryCriteriaStatDate>2000-03-03T00:00:00.0</ProtEntryCriteriaStatDate>
        <ProtEntryCriteriaEntryDate>2000-04-13T15:39:45.0</ProtEntryCriteriaEntryDate>
        <ProtEntryCriteriaEntryUser>SCHRISTE</ProtEntryCriteriaEntryUser>
        <ProtEntryCriteriaChangeUser>SCHRISTE</ProtEntryCriteriaChangeUser>
       </ProtEntryCriteria>
       <ProtObjectives>
        <ProtObjectivesText>I. Determine the response rate in patients with mycosis fungoides or Sezary syndrome treated with interleukin-2 (IL-2).

II. Determine the toxicity of this regimen in these patients.</ProtObjectivesText>
        <ProtObjectivesStat>on-line</ProtObjectivesStat>
        <ProtObjectivesStatDate>2000-03-03T00:00:00.0</ProtObjectivesStatDate>
        <ProtObjectivesEntryDate>2000-04-13T15:39:45.0</ProtObjectivesEntryDate>
        <ProtObjectivesEntryUser>SCHRISTE</ProtObjectivesEntryUser>
        <ProtObjectivesChangeUser>SCHRISTE</ProtObjectivesChangeUser>
       </ProtObjectives>
       <ProtOutline>
        <ProtOutlineText>This is a multicenter study.

Patients receive interleukin-2 subcutaneously for 4 consecutive days a week
for 6 consecutive weeks.  Treatment repeats every 8 weeks in the absence of
disease progression or unacceptable toxicity.  Patients who achieve complete
response or stable disease continue treatment for 2 courses past best
response.  Patients who demonstrate a persistent partial response continue
treatment in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for survival.</ProtOutlineText>
        <ProtOutlineStat>on-line</ProtOutlineStat>
        <ProtOutlineStatDate>2000-03-03T00:00:00.0</ProtOutlineStatDate>
        <ProtOutlineEntryDate>2000-04-13T15:39:45.0</ProtOutlineEntryDate>
        <ProtOutlineEntryUser>SCHRISTE</ProtOutlineEntryUser>
        <ProtOutlineChangeUser>SCHRISTE</ProtOutlineChangeUser>
       </ProtOutline>
       <ProtProjAccrual>
        <ProtProjAccrualText>A total of 15-35 patients will be accrued for this study.</ProtProjAccrualText>
        <ProtProjAccrualStat>on-line</ProtProjAccrualStat>
        <ProtProjAccrualStatDate>2000-03-03T00:00:00.0</ProtProjAccrualStatDate>
        <ProtProjAccrualEntryDate>2000-04-13T15:39:45.0</ProtProjAccrualEntryDate>
        <ProtProjAccrualEntryUser>SCHRISTE</ProtProjAccrualEntryUser>
        <ProtProjAccrualChangeUser>SCHRISTE</ProtProjAccrualChangeUser>
       </ProtProjAccrual>
       <ProtStudyParms>
        <ProtStudyParmsText>Not abstracted</ProtStudyParmsText>
        <ProtStudyParmsStat>on-line</ProtStudyParmsStat>
        <ProtStudyParmsStatDate>2000-03-03T00:00:00.0</ProtStudyParmsStatDate>
        <ProtStudyParmsEntryDate>2000-04-13T15:39:45.0</ProtStudyParmsEntryDate>
        <ProtStudyParmsEntryUser>SCHRISTE</ProtStudyParmsEntryUser>
        <ProtStudyParmsChangeUser>SCHRISTE</ProtStudyParmsChangeUser>
       </ProtStudyParms>
       <ProtStratification>
        <ProtStratificationText>Not abstracted</ProtStratificationText>
        <ProtStratificationStat>on-line</ProtStratificationStat>
        <ProtStratificationStatDate>2000-03-03T00:00:00.0</ProtStratificationStatDate>
        <ProtStratificationEntryDate>2000-04-13T15:39:45.0</ProtStratificationEntryDate>
        <ProtStratificationEntryUser>SCHRISTE</ProtStratificationEntryUser>
        <ProtStratificationChangeUser>SCHRISTE</ProtStratificationChangeUser>
       </ProtStratification>
       <ProtWarning>
        <ProtWarningText>The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer.  Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test.  The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment.  A responsible investigator associated with this clinical trial should be consulted before using this protocol.</ProtWarningText>
        <ProtWarningStat>on-line</ProtWarningStat>
        <ProtWarningStatDate>2000-03-03T00:00:00.0</ProtWarningStatDate>
        <ProtWarningEntryDate>2000-04-13T15:39:45.0</ProtWarningEntryDate>
        <ProtWarningEntryUser>SCHRISTE</ProtWarningEntryUser>
        <ProtWarningChangeUser>SCHRISTE</ProtWarningChangeUser>
       </ProtWarning>
       <ProtProdType>
        <ProtProdTypeProduct>Cancer Information Product</ProtProdTypeProduct>
        <ProtProdTypeCategory>Information Category</ProtProdTypeCategory>
        <ProtProdTypeName>treatment</ProtProdTypeName>
       </ProtProdType>
       <ProtProdType>
        <ProtProdTypeProduct>Rare Disease Information Product</ProtProdTypeProduct>
        <ProtProdTypeCategory>Information Category</ProtProdTypeCategory>
        <ProtProdTypeName>treatment</ProtProdTypeName>
       </ProtProdType>
       <PdqKey>14904</PdqKey>
      </Protocol>
